annual cash & cash equivalents:
$1.14B+$63.90M(+5.95%)Summary
- As of today (September 9, 2025), BMRN annual cash & cash equivalents is $1.14 billion, with the most recent change of +$63.90 million (+5.95%) on December 31, 2024.
- During the last 3 years, BMRN annual cash & cash equivalents has risen by +$123.83 million (+12.21%).
- BMRN annual cash & cash equivalents is now -18.50% below its all-time high of $1.40 billion, reached on December 31, 2017.
Performance
BMRN Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$1.43B+$159.79M(+12.56%)Summary
- As of today (September 9, 2025), BMRN quarterly cash & cash equivalents is $1.43 billion, with the most recent change of +$159.79 million (+12.56%) on June 30, 2025.
- Over the past year, BMRN quarterly cash & cash equivalents has increased by +$207.77 million (+16.97%).
- BMRN quarterly cash & cash equivalents is now -4.88% below its all-time high of $1.51 billion, reached on September 30, 2020.
Performance
BMRN quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
BMRN Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +6.0% | +17.0% |
| 3 y3 years | +12.2% | +29.1% |
| 5 y5 years | +50.9% | +3.8% |
BMRN Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -11.9% | +12.2% | at high | +53.9% |
| 5 y | 5-year | -11.9% | +50.9% | -4.9% | +53.9% |
| alltime | all time | -18.5% | >+9999.0% | -4.9% | >+9999.0% |
BMRN Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $1.43B(+12.6%) |
| Mar 2025 | - | $1.27B(+11.8%) |
| Dec 2024 | $1.14B(+6.0%) | $1.14B(+22.3%) |
| Sep 2024 | - | $930.44M(-24.0%) |
| Jun 2024 | - | $1.22B(+17.0%) |
| Mar 2024 | - | $1.05B(-2.5%) |
| Dec 2023 | $1.07B(-16.9%) | $1.07B(-4.6%) |
| Sep 2023 | - | $1.13B(-3.9%) |
| Jun 2023 | - | $1.17B(+1.6%) |
| Mar 2023 | - | $1.15B(-10.8%) |
| Dec 2022 | $1.29B(+27.4%) | $1.29B(+1.4%) |
| Sep 2022 | - | $1.27B(+14.8%) |
| Jun 2022 | - | $1.11B(+5.1%) |
| Mar 2022 | - | $1.06B(+4.2%) |
| Dec 2021 | $1.01B(-4.8%) | $1.01B(-6.1%) |
| Sep 2021 | - | $1.08B(-3.9%) |
| Jun 2021 | - | $1.12B(+3.3%) |
| Mar 2021 | - | $1.09B(+2.1%) |
| Dec 2020 | $1.07B(+41.3%) | $1.07B(-29.2%) |
| Sep 2020 | - | $1.51B(+9.1%) |
| Jun 2020 | - | $1.38B(+60.8%) |
| Mar 2020 | - | $858.40M(+13.9%) |
| Dec 2019 | $753.81M(-30.5%) | $753.81M(+4.6%) |
| Sep 2019 | - | $720.79M(-1.4%) |
| Jun 2019 | - | $731.10M(-18.3%) |
| Mar 2019 | - | $894.85M(-17.5%) |
| Dec 2018 | $1.08B(-22.3%) | $1.08B(-24.9%) |
| Sep 2018 | - | $1.44B(+5.9%) |
| Jun 2018 | - | $1.36B(-1.4%) |
| Mar 2018 | - | $1.38B(-0.9%) |
| Dec 2017 | $1.40B(+76.8%) | $1.40B(+11.0%) |
| Sep 2017 | - | $1.26B(+70.5%) |
| Jun 2017 | - | $737.10M(+7.9%) |
| Mar 2017 | - | $682.87M(-13.5%) |
| Dec 2016 | $789.68M(+31.6%) | $789.68M(-23.7%) |
| Sep 2016 | - | $1.03B(+105.6%) |
| Jun 2016 | - | $503.29M(+10.2%) |
| Mar 2016 | - | $456.85M(-23.9%) |
| Dec 2015 | $599.97M(-36.5%) | $599.97M(-6.6%) |
| Sep 2015 | - | $642.07M(-6.8%) |
| Jun 2015 | - | $688.71M(-32.2%) |
| Mar 2015 | - | $1.02B(+7.5%) |
| Dec 2014 | $945.19M(+20.4%) | $945.19M(+41.8%) |
| Sep 2014 | - | $666.37M(-20.3%) |
| Jun 2014 | - | $836.62M(-5.7%) |
| Mar 2014 | - | $887.48M(+13.1%) |
| Dec 2013 | $784.72M(+74.1%) | $784.72M(+106.7%) |
| Sep 2013 | - | $379.65M(-5.2%) |
| Jun 2013 | - | $400.56M(-0.3%) |
| Mar 2013 | - | $401.88M(-10.8%) |
| Dec 2012 | $450.74M | $450.74M(+4.3%) |
| Sep 2012 | - | $432.13M(+6.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2012 | - | $404.69M(+72.9%) |
| Mar 2012 | - | $234.06M(+20.0%) |
| Dec 2011 | $195.09M(-28.8%) | $195.09M(-13.1%) |
| Sep 2011 | - | $224.37M(-13.3%) |
| Jun 2011 | - | $258.92M(+2.5%) |
| Mar 2011 | - | $252.58M(-7.9%) |
| Dec 2010 | $274.11M(-8.8%) | $274.11M(-22.1%) |
| Sep 2010 | - | $351.97M(+4.2%) |
| Jun 2010 | - | $337.67M(+4.3%) |
| Mar 2010 | - | $323.64M(+7.6%) |
| Dec 2009 | $300.68M(-46.9%) | $300.68M(-17.3%) |
| Sep 2009 | - | $363.44M(+4.8%) |
| Jun 2009 | - | $346.63M(-38.1%) |
| Mar 2009 | - | $559.62M(-2.8%) |
| Dec 2008 | $565.99M(-3.3%) | - |
| Jun 2008 | - | $575.66M(+0.2%) |
| Mar 2008 | - | $574.76M(-1.8%) |
| Dec 2007 | $585.59M(+102.7%) | $585.59M(-0.2%) |
| Sep 2007 | - | $586.69M(-0.2%) |
| Jun 2007 | - | $587.71M(+115.0%) |
| Mar 2007 | - | $273.31M(-5.4%) |
| Dec 2006 | $288.85M(+504.4%) | $288.85M(-1.7%) |
| Sep 2006 | - | $293.90M(-3.9%) |
| Jun 2006 | - | $305.90M(-12.0%) |
| Mar 2006 | - | $347.69M(+627.5%) |
| Dec 2005 | $47.79M(-35.5%) | $47.79M(-27.5%) |
| Sep 2005 | - | $65.91M(+145.9%) |
| Jun 2005 | - | $26.80M(-37.2%) |
| Mar 2005 | - | $42.69M(-42.4%) |
| Dec 2004 | $74.11M(-64.1%) | $74.11M(-33.7%) |
| Sep 2004 | - | $111.75M(-27.4%) |
| Jun 2004 | - | $153.92M(-25.4%) |
| Mar 2004 | - | $206.35M(-0.0%) |
| Dec 2003 | $206.36M(+178.9%) | $206.36M(-14.7%) |
| Sep 2003 | - | $241.89M(-9.2%) |
| Jun 2003 | - | $266.36M(+79.3%) |
| Mar 2003 | - | $148.58M(+100.8%) |
| Dec 2002 | $73.98M(+84.0%) | $73.98M(-14.4%) |
| Sep 2002 | - | $86.47M(-14.0%) |
| Jun 2002 | - | $100.56M(-12.4%) |
| Mar 2002 | - | $114.80M(+161.5%) |
| Sep 2001 | - | $43.91M(-26.7%) |
| Jun 2001 | - | $59.88M(+101.2%) |
| Mar 2001 | - | $29.77M(-26.0%) |
| Dec 2000 | $40.20M(+253.0%) | $40.20M(-15.4%) |
| Sep 2000 | - | $47.51M(-3.9%) |
| Jun 2000 | - | $49.41M(-11.2%) |
| Mar 2000 | - | $55.67M(+1354.1%) |
| Mar 1999 | - | $3.83M(-66.4%) |
| Dec 1998 | $11.39M(+65.3%) | - |
| Dec 1998 | - | $11.39M |
| Dec 1997 | $6.89M | - |
FAQ
- What is BioMarin Pharmaceutical Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for BioMarin Pharmaceutical Inc.?
- What is BioMarin Pharmaceutical Inc. annual cash & cash equivalents year-on-year change?
- What is BioMarin Pharmaceutical Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for BioMarin Pharmaceutical Inc.?
- What is BioMarin Pharmaceutical Inc. quarterly cash & cash equivalents year-on-year change?
What is BioMarin Pharmaceutical Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of BMRN is $1.14B
What is the all time high annual cash & cash equivalents for BioMarin Pharmaceutical Inc.?
BioMarin Pharmaceutical Inc. all-time high annual cash & cash equivalents is $1.40B
What is BioMarin Pharmaceutical Inc. annual cash & cash equivalents year-on-year change?
Over the past year, BMRN annual cash & cash equivalents has changed by +$63.90M (+5.95%)
What is BioMarin Pharmaceutical Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of BMRN is $1.43B
What is the all time high quarterly cash & cash equivalents for BioMarin Pharmaceutical Inc.?
BioMarin Pharmaceutical Inc. all-time high quarterly cash & cash equivalents is $1.51B
What is BioMarin Pharmaceutical Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, BMRN quarterly cash & cash equivalents has changed by +$207.77M (+16.97%)